Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
With a slew of major biologic blockbuster drugs up for patent expiry in the coming years, players involved in biosimilar production are leaving no stone unturned to cash in on the opportunity. Rising acceptance for biosimilars due to various reasons, such as cost difference is increasing competition. Even for those drugs, whose patent expiration in the US is several years away, biosimilars are already under development.
View full press release